# GASTO-1091 (NCT04085250)

> Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04085250
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Sun Yat-sen University
- Conditions: Stage III Non-small-cell Lung Cancer
- Interventions: Neoadjuvant therapy; Chemotherapy concurrent with radiotherapy; Radiotherapy; Nivolumab; Observation
- Enrollment: 264
- Primary outcome: Progression-free Survival

## Indexed commentary on GASTO-1091 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=gasto-1091-nct04085250